Cerenis appoints John Paolini as chief medical officer

pharmafile | November 29, 2011 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Cerenis 

The HDL drug specialist Cerenis Therapeutics has appointed Dr John Paolini as its new chief medical officer.

Dr Paolini will be responsible for the strategic planning and execution of the clinical trials for Cerenis’s portfolio of novel cardiovascular therapies.

He will also oversee Cerenis’s lead product, CER-001, a pre-beta HDL mimetic currently in Phase II clinical trials for patients with acute coronary syndrome.

Dr Paolini has more than 15 years of clinical and research experience in cardiovascular disease, the last decade being focused on clinical development in the pharmaceutical industry.

Advertisement

At his previous post at Bayer he led the clinical development Xarelto (rivaroxaban) programme, the novel anticoagulant agent for patients with atrial fibrillation.

He is board certified in cardiovascular disease, a fellow of the American College of Cardiology and has served as a clinical associate in cardiovascular medicine at the Hospital of the University of Pennsylvania. 

Related Content

No items found
The Gateway to Local Adoption Series

Latest content